#BlackFridaySales for lab work. Anyone interested?
#SkyNeph #SkyMed

The latest salvo in the hyponatremia wars takes off where Seethapathy left us (NEJM Evidence | NephJC). Last week, Juan Carlos Ayus published his latest study (JAMA Internal Medicine) on hyponatremia, a meta analysis of patient outcomes in the management of hyponatremia

pbfluids.com/2024/11/its-...

jamanetwork.com/journals/jam...

GLP-1 RAs may reduce the risk of cirrhosis progression and complications in patients with MASLD and DM, especially when started early. No benefit observed if initiated after cirrhosis onset. #LiverHealth #DiabetesCare #metabolicsyndrome

Dear #AskRenal friends - Finally, I have a feed up and running!
Still trying to get the repost and like feature working.
Feed: bsky.app/profile/did:...

Questions - DM me - @drnikhilshah.bsky.social
#NephSky

#MedSky

@nephjc.bsky.social l @hswapnil.bsky.social l @kidneyboy.bsky.social

bsky.app/profile/did:...

Here we go!!
#askrenal is back!

Will #finerenone become MRA of choice in #CHF for GDMT? Often these pts w soft BPs and unable to use #spironolactone in addition to ARNI. Also compelling if diabetic & proteinuric as well! Can titrate up to 40mg. #medsky #nephsky #AHA24

Another fail for Spironolactone 😰
Post MI
CLEAR trial, funded by CIHR

www.nejm.org/doi/full/10....

From #AHA24

10/10
Final thoughts:
⭐ Finerenone In DKD = ⬇️CV /Kidney outcomes

⭐ Finerenone in HFpEF =⬇️ CV death +HF events

⭐ Small % patients on background #flozin /GLP-1

⏰It’s Time to do some trials with combination therapy #flozin + finerenone ! #CONFIRMATIONHF #CONFIDENCE

Another feather in the cap! Benefits are endless. #flozin #SGLT2i #medsky #nephsky

Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up than 2 previous trials with semaglutide
nejm.org/doi/full/10....
in people with BMI >30; no data yet for HFpEF in people without obesity

Albuminuria, an established biomarker of the progression of CKD, is also recognized as a biomarker for the risk of CVD (ca. 2024)
#Nephpearls #NephSky #Cardiorenal

👉🏼 pubmed.ncbi.nlm.nih.gov/38214258/

Have followed multiple people across different specialties. Thanks to the starter packs! #medsky

#LBCT #SUMMIT trial #AHA24
💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity
📎 @NEJM www.nejm.org/doi/full/10....

So exciting! #SUMMIT trial, the first #HFpEF trial of incretin therapy with HF clinical outcomes as prespecified primary outcome. And #tirzepatide reduced CV death or worsening HF by significant 38%! Improvement in KCCQ quality of life by 7 pts, wt loss 12%, hsCRP reduction by 35%! #AHA24 #CardioSky

www.nejm.org/doi/full/10....
BROAD trial Presented at #AHA24
#skyneph

The discovery of the #aquaporin #AQP family of water channels has provided a molecular counterpart to the movement of water across biological membranes. This JASN review, discusses the concept of osmosis and its central relevance for #PeritonealDialysis. journals.lww.com/jasn/fulltex...

Just posting some great #Nephsky references here:

UW Nephrology Grand Rounds:
www.youtube.com/@universityo...

University of Ottawa Nephrology Grand Rounds:
www.youtube.com/@ottawanephr...

Rush University Biopsy Conference:
www.youtube.com/@rumc-biopyc...

Nephropocus
nephropocus.com

Slidedeck from an internal presentation on diabetic kidney disease 👇

Nephrologist's take on the effect and impact of SGLT-2 inhibitors, GLP-1 RAs and ns-MRA on #Kidney Disease in people with #diabetes #flozin #sglt2i #MRA #GLP1RA
#MedEd #MedSky #NephSky

www.slideshare.net/slideshow/ne...